American Home Products and Elan Join to Develop Alzheimer's Vaccine

American Home Products and Elan Join to Develop Alzheimer's Vaccine

Client News
American Home Products Corporation, one of the world's largest research-based pharmaceutical and health care products companies, recently formed a research alliance with Elan, the leading Irish pharmaceutical and biotechnology company, to develop a vaccine that may be used for the treatment of mild to moderate Alzheimer's disease and possibly to treat the onset of the disease.

Under the terms of the alliance, AHP and Elan will collaborate in the research, development and commercialization of an experimental therapy called AN-1792, which has shown in pre-clinical trials to reduce and prevent development of amyloid plaque, a substance that is thought to be associated with Alzheimer's. The alliance also includes a five-year research program for the discovery and characterization of additional products.

Members of Hale and Dorr's Life Sciences Group represented American Home Products in the establishment of this important alliance.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.